Paxlovid, Molnupiravir Access Threatened By ‘Dismal' Pharmacy Dispensing Fees, CMS Told
Executive Summary
Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.
You may also be interested in...
Letting Paxlovid Go: HHS Seeking To Buffer Drug’s Sticker Shock In ‘Cold’ Commercial World
HHS Secretary Becerra challenges the commercial price Pfizer chose for its COVID-19 therapeutic as the government transitions from being the primary US customer for the drug.
Medicare Part D Coverage For Obesity Drugs Urged By House Appropriations Panel
In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.
Test To Treat Tug-of-War: Pharmacy, Physician Groups Each Have Concerns With Biden COVID Plan
Community pharmacists say widespread implementation of Biden’s rapid pill dispensing initiative necessitates allowing pharmacists to prescribe Paxlovid and molnupiravir. But AMA worries that even clinic-based prescribing puts patients at risk because it bypasses primary care doctors.